Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051516 | 0.84 | HPGDS (0.54) | HPGDSNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL179333 | 0.82 | LMNA (0.50) | LMNAMEN1KMT2AHPGDSNPC1 | |
| SCHEMBL676678 | 0.82 | HPGDS (0.56) | HPGDSNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL11994377 | 0.81 | HDAC3 (0.42) | LMNAMEN1KMT2AEGLN1NPC1 | |
| SCHEMBL24721140 | 0.80 | RXRA (0.49) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL14463185 | 0.80 | HPGDS (0.38) | LMNAMEN1KMT2AHPGDSPIK3CD | |
| SCHEMBL10313050 | 0.79 | HPGDS (0.43) | LMNAMEN1KMT2AHPGDSNPC1 | |
| SCHEMBL889387 | 0.79 | EGLN1 (0.44) | LMNAMEN1KMT2AEGLN1NPC1 | |
| SCHEMBL27435742 | 0.79 | EGLN1 (0.44) | LMNAEGLN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13886044 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2AHPGDSNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2015-12-03 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | LMNA 2800/4885MEN1 4782/4885KMT2A 2957/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | LMNA 886/4885MEN1 4836/4885KMT2A 1664/4885 |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | USP1, UHRF1, UBQLN1 | LMNA 3488/4885MEN1 3189/4885KMT2A 1825/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | LMNA 821/4885MEN1 4835/4885KMT2A 1725/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | LMNA 2791/4885MEN1 4817/4885KMT2A 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.